Literature DB >> 16103072

Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis.

Jose G Trevino1, Justin M Summy, Michael J Gray, Monique B Nilsson, Donald P Lesslie, Cheryl H Baker, Gary E Gallick.   

Abstract

Interleukin-8 (IL-8) is an angiogenic factor that promotes growth of pancreatic tumors. The purpose of this study was to determine if c-Src, a protein tyrosine kinase frequently overexpressed in pancreatic cancer, regulated IL-8 expression and to elucidate the Src-mediated signaling pathways that contribute to angiogenesis in pancreatic adenocarcinoma cells. In a panel of pancreatic cancer cell lines, expression of total and activated Src correlated with IL-8 production. Furthermore, ectopic expression of activated Src in PANC-1 cells with low endogenous Src activity significantly increased IL-8 production (P < 0.005). In contrast, pharmacologic inhibition of endogenous c-Src kinase activity or small interfering RNA-mediated "knockdown" of c-Src expression in L3.6pl cells with high Src expression and activity caused significant decreases in IL-8 production (P < 0.005). Inhibition of c-Src activity resulted in decreased phosphorylation of Akt, p38, and extracellular signal-regulated kinase (Erk)-1/2. Significant (P < 0.005) dose-dependent decreases were observed in IL-8 expression by inhibiting Src-dependent signaling molecules Erk-1/2 and p38 but not phosphatidylinositol 3-kinase. To assess the relevance of Src inhibition to angiogenesis, in vivo gelfoam assays were done. Robust infiltration of vessels was observed in gelfoam saturated with conditioned medium from pancreatic carcinoma cells. This angiogenesis was nearly abrogated in gelfoams saturated with conditioned medium from cells treated with the Src family kinase inhibitor, PP2 (P < 0.001). Thus, c-Src regulates critical "downstream" signaling pathways that contribute to expression of IL-8 in human pancreatic tumor cells, suggesting c-Src may be a target for therapeutic intervention in pancreatic adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16103072     DOI: 10.1158/0008-5472.CAN-04-3858

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

1.  Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancer.

Authors:  Daniel Delitto; Chelsey Perez; Song Han; David H Gonzalo; Kien Pham; Andrea E Knowlton; Christina L Graves; Kevin E Behrns; Lyle L Moldawer; Ryan M Thomas; Chen Liu; Thomas J George; Jose G Trevino; Shannon M Wallet; Steven J Hughes
Journal:  Cancer Immunol Immunother       Date:  2015-09-30       Impact factor: 6.968

2.  1'-Acetoxychavicol acetate suppresses angiogenesis-mediated human prostate tumor growth by targeting VEGF-mediated Src-FAK-Rho GTPase-signaling pathway.

Authors:  Xiufeng Pang; Li Zhang; Li Lai; Jing Chen; Yuanyuan Wu; Zhengfang Yi; Jian Zhang; Weijing Qu; Bharat B Aggarwal; Mingyao Liu
Journal:  Carcinogenesis       Date:  2011-03-22       Impact factor: 4.944

3.  Protease activated receptor-1 inhibits the Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype.

Authors:  Gabriel J Villares; Maya Zigler; Andrey S Dobroff; Hua Wang; Renduo Song; Vladislava O Melnikova; Li Huang; Russell R Braeuer; Menashe Bar-Eli
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

4.  Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors.

Authors:  Puja Gaur; Eric L Sceusi; Shaija Samuel; Ling Xia; Fan Fan; Yunfei Zhou; Jia Lu; Federico Tozzi; Gabriel Lopez-Berestein; Pablo Vivas-Mejia; Asif Rashid; Jason B Fleming; Eddie K Abdalla; Steven A Curley; Jean-Nicolas Vauthey; Anil K Sood; James C Yao; Lee M Ellis
Journal:  Gastroenterology       Date:  2011-07-30       Impact factor: 22.682

5.  A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors.

Authors:  Niharika B Mettu; Donna Niedzwiecki; Christel Rushing; Andrew B Nixon; Jingquan Jia; Sherri Haley; Wanda Honeycutt; Herbert Hurwitz; Johanna C Bendell; Hope Uronis
Journal:  Cancer Chemother Pharmacol       Date:  2019-03-20       Impact factor: 3.333

6.  Aflatoxin B1 induces Src phosphorylation and stimulates lung cancer cell migration.

Authors:  Anguo Cui; Hui Hua; Ting Shao; Peiying Song; Qingbin Kong; Ting Luo; Yangfu Jiang
Journal:  Tumour Biol       Date:  2015-03-29

Review 7.  Src signaling pathways in prostate cancer.

Authors:  Andreas Varkaris; Anastasia D Katsiampoura; John C Araujo; Gary E Gallick; Paul G Corn
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

8.  Primary outgrowth cultures are a reliable source of human pancreatic stellate cells.

Authors:  Song Han; Daniel Delitto; Dongyu Zhang; Heather L Sorenson; George A Sarosi; Ryan M Thomas; Kevin E Behrns; Shannon M Wallet; Jose G Trevino; Steven J Hughes
Journal:  Lab Invest       Date:  2015-08-31       Impact factor: 5.662

9.  Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.

Authors:  Scott Kopetz; Donald P Lesslie; Nikolas A Dallas; Serk I Park; Marjorie Johnson; Nila U Parikh; Michael P Kim; James L Abbruzzese; Lee M Ellis; Joya Chandra; Gary E Gallick
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

10.  Antivascular therapy for epithelial ovarian cancer.

Authors:  Francois P Duhoux; Jean-Pascal Machiels
Journal:  J Oncol       Date:  2009-12-23       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.